10-Q: VSee Health Reports Q3 Revenue Growth Amid Going Concern Doubt

VSee Health, Inc. reported a 60% revenue increase for the nine months ended September 30, 2025, driven by its iDoc acquisition, but faces substantial doubt about its ability to continue as a going concern due to persistent operating losses and liquidity challenges.

Summary

• Total revenues for the nine months ended September 30, 2025, increased by $4,005,261 (60%) to $10,692,259, compared to $6,686,998 for the same period in 2024.
• The revenue growth was primarily driven by the iDoc acquisition, contributing $3,395,089 (289%) from higher telehealth service volume and patient fees.
• Net loss for the nine months ended September 30, 2025, significantly decreased by $47,631,445 (87%) to $(6,862,468), compared to $(54,493,913) in 2024, mainly due to the absence of a $56,675,210 goodwill impairment charge recorded in the prior year.
• Cost of revenues for the nine months ended September 30, 2025, increased by $3,279,943 (173%) to $5,170,500, primarily due to higher compensation expenses for medical providers and increased procurement of medical devices for the HHS contract.
• Operating expenses decreased by $52,254,565 (82%) for the nine months ended September 30, 2025, largely due to the absence of the prior year's goodwill impairment charge, but were partially offset by higher general and administrative expenses and compensation-related expenses.
• The company's accumulated deficit increased to $(74,566,341) as of September 30, 2025, from $(67,703,873) as of December 31, 2024.
• Cash and cash equivalents increased by $146,644 to $472,759 as of September 30, 2025, from $326,115 as of December 31, 2024.
• The company has material weaknesses in internal control over financial reporting, including insufficient accounting personnel, ineffective IT General Controls, and lack of formalized control oversight, which contributed to the late filing of this report.

Sentiment

Score: 2

Explanation: While revenue growth is positive, the company faces severe financial distress, including substantial doubt about its going concern status, persistent operating losses, increasing accumulated deficit, multiple debt defaults, and material weaknesses in internal controls. Significant dilution from recent debt-to-equity conversions further weighs on shareholder value.

Positives

• Total revenues increased by 60% for the nine months ended September 30, 2025, reaching $10,692,259, demonstrating significant top-line growth.
• The iDoc acquisition contributed substantially to revenue growth, increasing telehealth service volume and patient fees by $1,983,122 and $1,418,847, respectively, for the nine-month period.
• Professional services and other fees saw a 120% increase, or $1,378,923, driven by higher medical device sales and services related to a new HHS contract.
• Net loss decreased by 87% for the nine months ended September 30, 2025, primarily due to the absence of a large goodwill impairment charge from the prior year, indicating an improvement in reported profitability metrics.
• The company won new contracts with larger hospitals and entered new markets, demonstrating its ability to generate positive revenue growth from its robust pipeline.

Negatives

• The company has a substantial doubt about its ability to continue as a going concern due to persistent operating losses and a deteriorating liquidity position.
• Cost of revenues increased significantly by 173% for the nine months ended September 30, 2025, outpacing revenue growth and impacting gross margin percentage.
• Subscription fees declined by 16% for the nine months ended September 30, 2025, due to reduced recurring enterprise-level subscriptions.
• Technical engineering services decreased by 23% for the nine months ended September 30, 2025, due to lower client utilization.
• Total liabilities increased by $4,271,644 to $24,282,620 as of September 30, 2025, from $20,010,976 as of December 31, 2024.
• The accumulated deficit worsened to $(74,566,341) as of September 30, 2025, from $(67,703,873) as of December 31, 2024.
• Multiple promissory notes and lines of credit are currently in default, including those assumed from iDoc and related party loans.
• The company identified material weaknesses in internal control over financial reporting, including insufficient accounting personnel, ineffective IT General Controls, and lack of formalized control oversight, which contributed to the late filing of this report.
• Significant dilution occurred post-quarter end with the conversion of multiple convertible notes (Quantum, Exchange, September 2024, March 2025) into millions of common shares.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least one year due to persistent operating losses and negative operating cash flow.
• The company's plans to alleviate going concern concerns, including revenue enhancement and additional financing, may not be successful or achieved within one year.
• Material weaknesses in internal control over financial reporting, such as insufficient accounting personnel, ineffective IT General Controls, and lack of formalized control oversight, increase the risk of material financial misstatements.
• The company is involved in a pending lawsuit for alleged breach of contract and unjust enrichment, which could materially adversely affect its business, results of operations, and financial condition.
• Concentrations of credit risk exist with two customers representing 46% of total accounts receivable and 31% of total revenue for the three months ended September 30, 2025.
• The company relies on a single vendor for 16% of its total accounts payable and accrued liabilities as of September 30, 2025.
• The company's financial models for goodwill and intangible asset impairment contain significant assumptions and estimates that could materially affect operating results if they change.
• The company's ability to secure additional financing is crucial, and there is no assurance that negotiations with investors will be successful.
• The company's debt instruments, particularly convertible notes, are subject to fair value remeasurement, which can lead to significant non-cash gains or losses in earnings.

Future Outlook

Management believes the rapid transformation of the telehealth market indicates strong future growth and that its current offerings provide an attractive value proposition, driving higher market share. The company plans to leverage industry relationships to expand its customer base and invest in new technology and product offerings to drive long-term success. However, there is no assurance that plans to alleviate going concern doubts will be successful within one year.

Management Comments

• "We believe that the rapid transformation of the telehealth market indicates strong future growth of the market, and our current offerings provide an attractive value proposition to health systems, medical groups, and individual medical practitioners, driving higher market share."
• "We plan to continue to harness our scale to further grow the value proposition of our platform for all stakeholders."
• "We plan to leverage our industry relationships with government, hospital systems and insurance providers to increase our customer base."
• "We believe our ability to invest in new technology and develop new features, modules, and solutions will be critical to our long-term success."
• "Management has determined that the liquidity condition and historical operating losses raises substantial doubt about its ability to continue as a going concern for a period of time of least one year after the date that the accompanying condensed consolidated financial statements are issued."

Industry Context

The telehealth market is characterized by rapid transformation and is still in its infancy in terms of utilization and scope, representing less than 1% of total healthcare spending. VSee Health aims to capitalize on this growth by offering a scalable, API-driven platform for virtual healthcare delivery, integrating secure video streaming with medical device data and EMRs. The company's iDoc acquisition enhances its clinical capabilities in high-acuity patient care, addressing the shortage of intensivists and physician burnout in a post-COVID healthcare system. The company believes its technology solutions address existing limitations in telehealth, such as non-healthcare specific video solutions and poor integration of remote monitoring devices.

Comparison to Industry Standards

• The company's platform is designed to be HIPAA compliant and SOC2 externally audited, and GDPR compliant, supporting single-sign-on (SSO) and multi-factor-authentication (MFA), aligning with industry standards for data security and privacy.
• VSee Health's focus on 'no-code' and 'low-code' solutions for clinicians to configure workflows without extensive IT intervention aims to differentiate it from competitors by addressing a common pain point in healthcare technology adoption.
• The company's strategy to provide 'elite physician services' in intensive care units, including neuro-critical care, positions it in a high-acuity segment, potentially offering higher value services compared to general telehealth providers.
• The company's claim that its technology solutions 'meet the performance and compliance standards in healthcare, increase the sharing of patient history, files and scheduling are integrated into the video view for doctors, create sophisticated video engagement between patients, staff and doctors and seamlessly integrate patients records to provide more comprehensive telehealth care' suggests an ambition to exceed basic industry offerings, though specific comparative metrics are not provided.

Corporate Governance

Legal Proceedings

• A lawsuit was filed against the company on July 25, 2024, alleging breach of contract and unjust enrichment, seeking payment under promissory notes, payments related to the Encompass Acquisition Agreement, interest, and attorney's fees. The company denied allegations and filed a counterclaim. Settlement discussions are ongoing, and management believes the resolution will not have a material adverse effect.

Related Party Transactions

• Due from related party (Imoigele Aisiku, former CEO of iDoc): $284,614 as of September 30, 2025. These transactions are unsecured and non-interest-bearing.
• Promissory notes from Milton Chen (then CEO of VSee Lab): Three notes totaling $323,000 in principal, all in default as of September 30, 2025, accruing interest at 26% from default date.
• Promissory note from a board member: $141,651 outstanding as of September 30, 2025, bearing no interest and secured by telepresence robots.
• Quantum Convertible Note: SCS Capital Partners LLC (a Sponsor affiliate) owns approximately 40.74% of the Quantum Investor.
• Consulting Services Agreement with SCS, LLC (Sponsor affiliate): $12,500 per month for business consulting and $2,500 per month for remote office space, plus stock issuances.
• Advances due to Sponsor and certain Sponsor affiliates: $51,900 remains due and payable as of September 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution from the conversion of multiple convertible notes into common stock, as evidenced by subsequent events where millions of shares were issued.
• Shareholders are exposed to substantial risk due to the company's going concern doubt, persistent operating losses, and increasing accumulated deficit.
• Creditors holding defaulted notes face uncertainty regarding repayment, although some have converted debt to equity.
• Employees of iDoc were subject to a common stock issuance obligation, which was recognized as a liability and remeasured at fair value.
• Customers may benefit from expanded telehealth offerings and new contracts, such as the HHS contract, but the company's financial instability could pose long-term risks to service continuity.

Next Steps

• Continue negotiations with an investor for additional financing to support working capital and growth initiatives.
• Remediate material weaknesses in internal control over financial reporting by enhancing processes, providing access to accounting literature, and increasing communication among personnel and third-party professionals.
• Address the pending lawsuit through ongoing settlement discussions.
• Make scheduled payments on the revised forbearance agreement, with the remaining balance due December 10, 2025.
• Manage the conversion of various convertible notes into common stock, as seen in subsequent events, which will impact share count and ownership structure.
• Comply with covenants and restrictions associated with new debt agreements, such as prohibitions on incurring additional indebtedness or paying dividends.

Key Dates

Recommendation

VSee Health, Inc. presents a highly speculative investment. While the company reported significant revenue growth, primarily driven by acquisitions and new contracts, this is overshadowed by severe financial distress. The explicit 'going concern' doubt, persistent operating losses, and a worsening accumulated deficit indicate fundamental instability. Multiple debt instruments are in default, highlighting critical liquidity issues. Furthermore, the identified material weaknesses in internal controls raise concerns about the reliability of financial reporting. The substantial dilution from recent debt-to-equity conversions, as detailed in subsequent events, will significantly impact existing shareholder value. For a seasoned investor, these factors collectively point to a high-risk profile with a strong likelihood of further value erosion.

Keywords

Telehealth, SEC Filing, 10-Q, Financial Results, VSee Health, iDoc Acquisition, Going Concern, Operating Losses, Revenue Growth, Internal Controls, Convertible Notes, Debt Default, Healthcare Technology, Financial Reporting, Liquidity